BiomX (PHGE-UN) Stock Analysis

What BiomX does

Headquartered in Ness Ziona, Israel, BiomX Inc. is a clinical-stage biotechnology company established in 2015, dedicated to advancing microbiome-based therapies. The firm harnesses both naturally occurring and genetically engineered bacteriophage technologies to precisely identify and eliminate detrimental bacterial strains. BiomX's therapeutic efforts span conditions impacting skin appearance, as well as a spectrum of chronic diseases, including inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). The company's robust development pipeline includes several promising candidates. BX004, a phage-based treatment for cystic fibrosis patients suffering from persistent Pseudomonas aeruginosa respiratory infections, is presently undergoing Phase 1b/2a clinical evaluation. Another key asset, BX005, is a topical phage cocktail currently in Phase 1/2 clinical studies, engineered to combat Staphylococcus aureus (S. aureus), a bacterium linked to various disease manifestations. Additionally, BX003, an orally administered phage cocktail, is progressing through Phase 1b/2a trials, targeting a specific gut bacterium found in individuals with IBD and PSC. Beyond these, BiomX is engaged in a colorectal cancer initiative that utilizes engineered phages with diverse therapeutic payloads, delivered intravenously to neutralize Fusobacterium nucleatum bacteria residing within the tumor's microenvironment.

Key metrics

ETFs linked to PHGE-UN

Broad-market and Healthcare sector ETFs an investor holding BiomX is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PHGE-UN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for BiomX?

BiomX trades under the ticker PHGE-UN on AMEX.

Which exchange is PHGE-UN listed on?

PHGE-UN is listed on AMEX.

What sector does BiomX operate in?

BiomX is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze PHGE-UN in a portfolio?

PortView shows PHGE-UN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.